Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2,000
Single User License Price INR 135
Corporate User License Price USD 6,000
Corporate User License Price INR 405
Site License Price USD 4,000
Site License Price INR 270
Request a Quote

Report Title

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline Review, H1 2018

Quote Request for License Type
License Type Price  
Single User License USD 2,000
Site License USD 4,000
Enterprise Wide License USD 6,000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline Review, H1 2018


Quote Request for License Type
License Type Price  
Single User License USD 2,000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline Review, H1 2018

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline Review, H1 2018



Executive Summary

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline Review, H1 2018

 

Summary

 

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Adrenoleukodystrophy - Pipeline Review, H1 2018, provides an overview of the Adrenoleukodystrophy (Genetic Disorders) pipeline landscape.

 

"Adrenoleukodystrophy is a disorder that occurs most often in males. It mainly affects the nervous system and the adrenal glands, which are small glands located on top of each kidney. Abetalipoproteinemia is also a kind of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Bassen-Kornzweig syndrome is a rare disease passed down through families in which a person is unable to fully absorb dietary fats through the intestines. The disease is caused by a defect in gene that tells the body to create lipoproteins. It is sympotomized by curvature of spine, muscle weakness, decrease of vision over time. Treatment involves large doses of vitamin supplements containing fat-soluble vitamins."

 

Report Highlights

 

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Adrenoleukodystrophy - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Adrenoleukodystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

 

The Adrenoleukodystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 2, 3 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 1 molecules, respectively.

 

Adrenoleukodystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

 

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

 

Scope

 

- The pipeline guide provides a snapshot of the global therapeutic landscape of Adrenoleukodystrophy (Genetic Disorders).

- The pipeline guide reviews pipeline therapeutics for Adrenoleukodystrophy (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Adrenoleukodystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Adrenoleukodystrophy (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Adrenoleukodystrophy (Genetic Disorders)

 

Reasons to buy

 

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Adrenoleukodystrophy (Genetic Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Adrenoleukodystrophy (Genetic Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Overview

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Companies Involved in Therapeutics Development

Applied Genetic Technologies Corp

bluebird bio Inc

MedDay SA

Minoryx Therapeutics sl

SOM Biotech SL

Viking Therapeutics Inc

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Drug Profiles

biotin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DRX-065 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DUOC-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

elivaldogene tavalentivec - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate ABCD1 for Adrenoleukodystrophy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MGTA-456 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MIN-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OP-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pioglitazone hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sobetirome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SOM-1201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

temsirolimus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VK-0214 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VK-2809 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Dormant Projects

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Product Development Milestones

Featured News & Press Releases

Apr 05, 2018: Magenta Therapeutics Announces First Patient Transplanted with MGTA-456 in Phase 2 Study in Inherited Metabolic Disorders

Dec 04, 2017: Orpheris Appoints Neil Warma to Board of Directors

Nov 29, 2017: Orpheris Obtains FDA Agreement On Single, Seamless Phase 1/2/3 Trial to Registration for Its Lead Drug Candidate, OP-101, as a Treatment for Childhood Cerebral Andrenoleukodystrophy (ccALD)

Nov 27, 2017: Orpheris Receives Orphan Drug Designation from the U.S. FDA for its Lead Drug Candidate, OP-101, for the Treatment of ccALD

Oct 23, 2017: Viking Therapeutics Presents Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy at the 87th Annual Meeting of the American Thyroid Association

Oct 04, 2017: Viking Therapeutics Announces Top-Line Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD)

Sep 28, 2017: NeuroVia Appoints Daniel Bradbury and Edward Kaye to its Board of Directors

Jul 21, 2017: SOM Biotech Opens New Office in US for Development of Adrenoleukodystrophy Drug, SOM1201

Dec 06, 2016: Viking Therapeutics Receives Orphan Drug Designation for VK0214 from the U.S. Food and Drug Administration for the Treatment of X-Linked Adrenoleukodystrophy

Sep 26, 2016: Viking Therapeutics Presents Positive Proof-of-Concept Data for VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy at the 86th Annual Meeting of the American Thyroid Association

Jul 26, 2016: Viking Therapeutics Announces Positive Top-Line Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD)

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

List of Tables

Number of Products under Development for Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline by Applied Genetic Technologies Corp, H1 2018

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline by bluebird bio Inc, H1 2018

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline by MedDay SA, H1 2018

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline by Minoryx Therapeutics sl, H1 2018

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline by SOM Biotech SL, H1 2018

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline by Viking Therapeutics Inc, H1 2018

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Dormant Projects, H1 2018

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Applied Genetic Technologies Corp

bluebird bio Inc

MedDay SA

Minoryx Therapeutics sl

SOM Biotech SL

Viking Therapeutics Inc

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutic Products under Development, Key Players in Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Pipeline Overview, Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Pipeline, Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand